- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03344133
Effect of Exercise Programme on Gut Microbiota, CVD Risk Factors and Appetite Regulation in Overweight Women
Effect of a 4-week Moderate Intensity Exercise Programme on Gut Microbiota, Cardiovascular Disease Risk Factors and Appetite Regulation in Overweight Women
Descripción general del estudio
Descripción detallada
Study Design: This is a randomized controlled study with a parallel design. Healthy, sedentary females aged between 18-45 years old will be recruited by means of an advertisement leaflet and word of mouth. Eligible participants will be enrolled in the study and will be randomly allocated to either exercise intervention (EX) or control (C) groups. The EX group will participate in a 4-week exercise intervention and the C group will be asked to continue with habitual life style for 4 weeks. Before and after 4 weeks of the intervention, participants from both groups will be asked to conduct a submaximal exercise test and a 7-hour experimental trial during which blood samples will be collected and metabolic rate will measured before and after consumption of standardized breakfast and lunch. Prior to the first 7-hour trial, participants will be asked to record diet for 3 days and replicate this diet prior to the second 7-hour trial. During these 3 days participants will provide fresh stool samples. Participants allocated to control group will have the option to participate in exercise intervention. A subset of the participants will repeat a 7-hour experimental trial and provide fresh stool and urine sample after 7 days of detraining.
Methods:
Preliminary Health Check: Participants will undertake a health screening questionnaire on the day of recruitment. Participants will also need to fill in Physical Activity Readiness Questionnaire (PARQ). Only participants who answered "no" to all questions in PARQ will conduct the submaximal exercise test.
Anthropometry: All participants will have height, weight and waist circumference measured at baseline and 4 weeks after the intervention.
7-hour Experimental Trial: Participants will attend the metabolic suite (New Lister Building, Glasgow Royal infirmary) in a fasted state at approximately 9.00 am. Participants will be instructed to lie supine on the couch, with the head resting on the pillow provided. Resting metabolic rate will be measured for 20 minutes and fasting blood sample will be obtained. A breakfast meal will be consumed immediately after the fasting sample and a lunch meal after 4 hours. Blood samples will be taken throughout a cannula hourly after breakfast and lunch consumption. Following each blood sample, metabolic rate will be measured for the duration of 20 minutes. Prior each blood sample, participants will fill in appetite questionnaires. Blood samples will be analysed for plasma lipids, glucose, insulin, inflammatory markers and gut appetite hormones using standard existing procedures.
Feacal sample collection & analysis: A disposable stool sample collection kit will be provided prior to the 7-hour trial day. Once collected, the container is sealed and placed in a larger sealable bag with a reducing sachet to remove oxygen and maintain anaerobic bacteria. Stool samples will be measured for changes in gut microbiota based on 16S rRNA amplicon sequencing, bacterial functional capacity and targeted bacterial metabolites (short chain fatty acids, sulphide, ammonia).
Exercise Training Programme: Exercise training will consist of 4 weekly sessions of endurance type exercise (cycling and running) lasting for 30, 40, 50, 60 minutes in the week 1, 2, 3 and 4 respectively. The time and day of each training trial will be agreed between the investigator and the participant and will be based around the participant's availability. All exercise sessions will be supervised by a researcher.
Submaximal Exercise Test: Participants will exercise on treadmill at gradually increasing intensities until 85% of maximal heart rate. During the last minute of each of the intensities heart rate will be measured and expired air will be collected by Douglas bag technique and analysed for oxygen consumption and carbon dioxide production. Relation between heart rate and rate of oxygen consumption will be used to predict maximal oxygen consumption, a marker of cardio-respiratory fitness.
Tipo de estudio
Inscripción (Anticipado)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Glasgow, Reino Unido, G312ER
- Reclutamiento
- School of Medicine, University of Glasgow / New Lister Building, Glasgow Royal Infirmary
-
Contacto:
- Eleni Rizou, BSc MSc
- Correo electrónico: e.rizou.1@research.gla.ac.uk
-
Contacto:
- Konstantinos Gerasimidis, BSc MSc PhD
- Correo electrónico: Konstantinos.Gerasimidis@glasgow.ac.uk
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Healthy, sedentary females, BMI>25 kg/m2, on a stable body weight for the last 3 months
Exclusion Criteria:
- Acute or chronic illness, use of antibiotics the past 3 months, smoking
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Exercise
4-week moderate intensity exercise programme
|
4-week moderate intensity exercise programme
|
Sin intervención: Control
4 weeks of habitual life style
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Gut microbiota composition
Periodo de tiempo: 12 months
|
Changes in the gut microbiota composition measured by 16S rRNA amplicon sequencing.
|
12 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Interleukin-6 (IL-6)
Periodo de tiempo: 3 months
|
Changes in fasting and postprandial interleukin-6 pre- and post-interventions measured by Human IL-6 ELISA Ready-Set-Go (Affymetrix, eBioscience)
|
3 months
|
Glucose
Periodo de tiempo: 3 months
|
Changes in fasting glucose pre- and post-interventions measured by Randox Glucose
|
3 months
|
Triglycerides
Periodo de tiempo: 3 months
|
Changes in fasting and postprandial triglycerides pre- and post-interventions measured by Randox Triglycerides
|
3 months
|
Insulin
Periodo de tiempo: 3 months
|
Changes in fasting insulin pre- and post-interventions measured by Mercodia Insulin ELISA
|
3 months
|
Peptide YY (PYY)
Periodo de tiempo: 12 months
|
Changes in fasting and postprandial peptide YY pre- and post-interventions measured by Human PYY (Total) ELISA (Merc Millipore)
|
12 months
|
Glucagon-like peptide-1 (GLP-1)
Periodo de tiempo: 12 months
|
Changes in fasting and postprandial glucagon-like peptide-1 pre- and post-interventions measured by GLP-1 Total ELISA (Merc Millipore)
|
12 months
|
Subjective appetite
Periodo de tiempo: 12 months
|
Changes in subjective appetite (hunger, satiety, fullness, prospective food consumption, desire to eat) pre- and post-interventions measured by Visual Analogue Scales (VAS) where respondents specify their level of agreement to a statement by indicating a position along a continuous line between two end-points (minimum score is 0 and maximum score is 100)
|
12 months
|
Faecal short-chain fatty acids
Periodo de tiempo: 12 months
|
Changes in concentrations of feacal short-chain fatty acids pre- and post-interventions measured by TRACE 2000 Gas Chromatography (ThermoQuest Ltd)
|
12 months
|
Faecal pH
Periodo de tiempo: 1 month
|
Changes in feacal pH between pre- and post-intervention measured by Hanna HI 98140
|
1 month
|
Body weight
Periodo de tiempo: 1 month
|
Differences in body weight (kilograms) between pre- and post-intervention measured by TANITA scales (TBF-300)
|
1 month
|
Height
Periodo de tiempo: 1 month
|
Height (meters) measured by stadiometer, a vertical ruler with a sliding horizontal paddle which is adjusted to rest on the top of the head
|
1 month
|
Body fat (kilograms)
Periodo de tiempo: 1 month
|
Differences in body fat expressed in kilograms between pre- and post-intervention measured by TANITA scales (TBF-300)
|
1 month
|
Body fat (% percentage)
Periodo de tiempo: 1 month
|
Differences in body fat expressed as percentage (%) (proportion of fat to the total body weight) between pre- and post-intervention measured by TANITA scales (TBF-300)
|
1 month
|
Body Mass Index (BMI)
Periodo de tiempo: 1 month
|
Differences in body mass index (weight and height will be combined to report BMI in kg/m^2) between pre- and post-intervention measured by TANITA scales (TBF-300)
|
1 month
|
Dietary Intake
Periodo de tiempo: 6 months
|
Energy intake and macro nutrient intake using WinDiets software based on food composition tables
|
6 months
|
Maximum Oxygen Consumption
Periodo de tiempo: 2 weeks
|
Maximum Oxygen Consumption (ml/kg/min) measured before and after the interventions by Servomex Gas Analyser
|
2 weeks
|
Energy substrate oxidation
Periodo de tiempo: 6 months
|
Fat and carbohydrate oxidation in the fasted and postprandial state measured before and after the interventions using indirect calorimetry (Oxycon Pro)
|
6 months
|
Resting Metabolic Rate
Periodo de tiempo: 2 month
|
Resting metabolic rate was measured before and after the interventions (Oxycon Pro)
|
2 month
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Konstantinos Gerasimidis, BSc MSc PhD, University of Glasgow
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 200140132
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Sobrepeso y Obesidad
-
UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI); Food and Drug Administration (FDA)Aún no reclutandoUso de Little Cigars and Cigarrillos (LCC)Estados Unidos
-
Bambino Gesù Hospital and Research InstituteTerminadoObesidad Pediátrica Severa (IMC > 97° pc -Según Centers for Disease Control and Prevention IMC Charts-) | Pruebas de función hepática alterada | Intolerancia glucémicaItalia